Choroidal Thickness Biomarkers in Ocular Microvascular Health

Abstract

Choroidal thickness, as measured by enhanced depth imaging optical coherence tomography (EDI-OCT), is emerging as a robust biomarker reflecting ocular microvascular health. This review synthesizes contemporary evidence on the clinical utility, pathophysiological relevance, and diagnostic implications of choroidal thickness in various ocular and systemic microvascular diseases. The article provides a comprehensive overview of epidemiology, risk factors, clinical presentations, diagnostic advances, management strategies, and evolving guideline recommendations, emphasizing the translational potential of choroidal biomarkers for early detection, monitoring, and therapeutic decision-making in microvascular disorders affecting the eye.

Introduction

The choroid is a highly vascularized tissue critical for retinal nourishment and homeostasis. Advances in non-invasive imaging, particularly EDI-OCT, have facilitated in vivo quantification of choroidal thickness, enabling clinicians and researchers to investigate its role as a biomarker of ocular and systemic microvascular health. Variations in choroidal thickness have been linked to a spectrum of retinal and systemic diseases, including diabetic retinopathy, hypertensive retinopathy, age-related macular degeneration (AMD), and central serous chorioretinopathy (CSC). Understanding the clinical and mechanistic implications of choroidal thickness is essential for optimizing patient care and informing research directions in microvascular ophthalmology.

Epidemiology / Disease Burden

Microvascular disorders of the eye contribute significantly to global visual morbidity. Diabetic retinopathy alone affects over 100 million people worldwide, while AMD and hypertensive retinopathy are also prevalent among aging populations. Epidemiological studies demonstrate that altered choroidal thickness is associated with increased disease burden in these entities. For example, reduced choroidal thickness often correlates with advanced stages of diabetic and hypertensive retinopathy, whereas increased thickness is a hallmark of CSC. These associations underscore the potential of choroidal biomarkers for risk stratification and population-level screening in high-risk cohorts.

Pathophysiology

The choroid supports the outer retina via its dense vascular network. Dysregulation of choroidal blood flow, endothelial dysfunction, and inflammatory cascades can alter choroidal thickness, reflecting underlying microvascular pathology. In diabetes, chronic hyperglycemia leads to microangiopathy and choroidal thinning due to capillary dropout and ischemia. Conversely, in CSC, hyperpermeability and choroidal congestion result in thickening. Choroidal thickness thus captures distinct pathophysiological processes, providing mechanistic insights into disease evolution and progression. Moreover, systemic factors such as hypertension, dyslipidemia, and systemic inflammatory states modulate choroidal structure through neurovascular and hormonal pathways.

Risk Factors

Several modifiable and non-modifiable factors influence choroidal thickness and its interpretation as a biomarker. Age-related thinning is well-documented, with studies reporting a decrement of 1.5–4 μm per year after the fourth decade of life. Systemic hypertension, poorly controlled diabetes, smoking, and dyslipidemia are associated with reduced choroidal thickness, while male sex and certain ethnicities (e.g., East Asians) exhibit inherently thicker choroids. Topical and systemic corticosteroids can induce choroidal thickening, as seen in CSC. Recognizing these determinants is crucial for contextualizing choroidal measurements in clinical practice and research.

Clinical Features

Altered choroidal thickness often precedes overt fundoscopic abnormalities in microvascular diseases. In diabetic eyes, choroidal thinning may signal early microvascular compromise before retinopathy becomes clinically apparent. In AMD, progressive choroidal atrophy is associated with geographic atrophy and visual dysfunction. CSC is characterized by a thickened choroid with serous retinal detachment. Recognizing patterns of choroidal alteration aids differential diagnosis and prognostication, particularly when clinical signs are subtle or ambiguous.

Diagnosis

EDI-OCT is the gold standard for non-invasive assessment of choroidal thickness, providing high-resolution, reproducible measurements. Choroidal imaging protocols typically involve subfoveal or macular mapping, with normative databases stratified by age, sex, and ethnicity. Ancillary modalities such as swept-source OCT and OCT angiography offer additional functional and structural insights, including choriocapillaris flow defects and vascular remodeling. Integration of choroidal thickness metrics with other imaging biomarkers enhances diagnostic precision in retinal vascular diseases, uveitis, and choroidal tumors.

Treatment & Management

Choroidal thickness serves as a dynamic biomarker to monitor disease activity and therapeutic response in various microvascular conditions. For instance, anti-VEGF therapy in neovascular AMD is often accompanied by choroidal thinning, correlating with improved visual outcomes. In diabetic macular edema, choroidal measurements may help predict treatment response and risk of recurrence. In CSC, mineralocorticoid receptor antagonists and photodynamic therapy are associated with normalization of choroidal thickness and clinical resolution. Personalized management strategies increasingly consider choroidal biomarkers alongside traditional clinical and imaging parameters.

Recent Advances / Emerging Therapies

Recent research has focused on refining choroidal imaging techniques and exploring novel therapeutic interventions targeting choroidal vasculature. Artificial intelligence algorithms are being developed to automate choroidal thickness measurement and integrate it with multimodal imaging data for enhanced risk stratification. Pharmacologic agents modulating choroidal blood flow and vascular permeability, such as adrenergic antagonists and novel anti-inflammatory compounds, are in early clinical trials. These advances hold promise for expanding the therapeutic landscape and improving outcomes in microvascular ocular diseases.

Guideline Recommendations

International societies, including the American Academy of Ophthalmology and the European Society of Retina Specialists, recognize the value of choroidal thickness assessment in the workup and monitoring of retinal vascular disorders. Current guidelines endorse the use of EDI-OCT in cases of unexplained visual loss, ambiguous fundus findings, and for follow-up of known microvascular pathology. However, further standardization of measurement protocols and normative reference ranges is warranted to enhance clinical applicability and research reproducibility.

Conclusion

Choroidal thickness is a clinically meaningful, mechanism-based biomarker that offers unique insights into ocular microvascular health. Its integration into routine ophthalmic practice supports early diagnosis, risk stratification, and tailored management of a spectrum of retinal and systemic microvascular diseases. Ongoing research and technological innovation are expected to further refine its utility and establish standardized guidelines for its implementation in clinical and research settings.